<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37261358</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Loss of interleukin-1 beta is not protective in the lupus-prone NZM2328 mouse model.</ArticleTitle><Pagination><StartPage>1162799</StartPage><MedlinePgn>1162799</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1162799</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1162799</ELocationID><Abstract><AbstractText>Aberrant activation of the innate immune system is a known driver of lupus pathogenesis. Inhibition of the inflammasome and its downstream signaling components in murine models of lupus has been shown to reduce the severity of disease. Interleukin-1 beta (IL-1&#x3b2;) is a proinflammatory cytokine released from cells following inflammasome activation. Here, we examine how loss of IL-1&#x3b2; affects disease severity in the lupus-prone NZM2328 mouse model. We observed a sex-biased increase in immune complex deposition in the kidneys of female mice in the absence of IL-1&#x3b2; that corresponds to worsened proteinuria. Loss of IL-1&#x3b2; did not result in changes in overall survival, anti-dsDNA autoantibody production, or renal immune cell infiltration. RNA-sequencing analysis identified upregulation of TNF and IL-17 signaling pathways specifically in females lacking IL-1&#x3b2;. Increases in these signaling pathways were also found in female patients with lupus nephritis, suggesting clinical relevance for upregulation of these pathways. Together, these data suggest that inhibition of the inflammasome or its downstream elements that block IL-1&#x3b2; signaling may need to be approached with caution in SLE, especially in patients with renal involvement to prevent potential disease exacerbation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Loftus, Liu, Berthier, Gudjonsson, Gharaee-Kermani, Tsoi and Kahlenberg.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loftus</LastName><ForeName>Shannon N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jianhua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berthier</LastName><ForeName>Celine C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudjonsson</LastName><ForeName>Johann E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gharaee-Kermani</LastName><ForeName>Mehrnaz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsoi</LastName><ForeName>Lam C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahlenberg</LastName><ForeName>J Michelle</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AR076975</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK081943</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AR072129</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UC2 AR081033</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AR075043</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058847" MajorTopicYN="Y">Inflammasomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">inflammasome</Keyword><Keyword MajorTopicYN="N">interleukin-1beta (IL-1&#xdf;)</Keyword><Keyword MajorTopicYN="N">lupus</Keyword><Keyword MajorTopicYN="N">nephritis</Keyword><Keyword MajorTopicYN="N">proteinuria</Keyword></KeywordList><CoiStatement>JMK has received grant support from Q32 Bio, Celgene/Bristol-Myers Squibb, Ventus Therapeutics, Rome Therapeutics, and Janssen. JMK has served on advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, EMD serrano, Gilead, GlaxoSmithKline, Aurinia Pharmaceuticals, Rome Therapeutics, and Ventus Therapeutics. JEG has received support from Eli Lilly, Janssen, BMS, Sanofi, Prometheus, Almirall, Kyowa-Kirin, Novartis, AnaptysBio, Boehringer Ingelheim, Regeneron, AbbVie, and Galderma. LT has received support from Janssen, Novartis, and Galderma. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>1</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>1</Day><Hour>10</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37261358</ArticleId><ArticleId IdType="pmc">PMC10227599</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1162799</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Woo JMP, Parks CG, Jacobsen S, Costenbader KH, Bernatsky S. The role of environmental exposures and gene-environment interactions in the etiology of systemic lupus erythematous. J Internal Med (2022) 291(6):755&#x2013;78. doi:&#xa0;10.1111/joim.13448</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13448</ArticleId><ArticleId IdType="pubmed">35143075</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;ckel T, Basta F, Weinmann-Menke J, Schwarting A. B cell activating factor (Baff): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (Sle). Autoimmun Rev (2021) 20(2):102736. doi:&#xa0;10.1016/j.autrev.2020.102736</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102736</ArticleId><ArticleId IdType="pubmed">33333233</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirobhushanam S, Lazar S, Kahlenberg JM. Interferons in systemic lupus erythematosus. Rheumatic Dis Clinics North America (2021) 47(3):297&#x2013;315. doi:&#xa0;10.1016/j.rdc.2021.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2021.04.001</ArticleId><ArticleId IdType="pmc">PMC8254852</ArticleId><ArticleId IdType="pubmed">34215365</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YR, Hsing CH, Chiu CJ, Huang HY, Hsu YH. Roles of il-1 and il-10 family cytokines in the progression of systemic lupus erythematosus: friends or foes? IUBMB Life (2022) 74(2):143&#x2013;56. doi:&#xa0;10.1002/iub.2568</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iub.2568</ArticleId><ArticleId IdType="pubmed">34668305</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzov&#xe1; D, et al. . A phase iii, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits b lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis rheumatism (2011) 63(12):3918&#x2013;30. doi:&#xa0;10.1002/art.30613</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30613</ArticleId><ArticleId IdType="pmc">PMC5007058</ArticleId><ArticleId IdType="pubmed">22127708</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. . Trial of anifrolumab in active systemic lupus erythematosus. New Engl J Med (2020) 382(3):211&#x2013;21. doi:&#xa0;10.1056/NEJMoa1912196</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlenberg JM, Carmona-Rivera C, Smith CK, Kaplan MJ. Neutrophil extracellular trap-associated protein activation of the Nlrp3 inflammasome is enhanced in lupus macrophages. J Immunol (Baltimore Md 1950) (2013) 190(3):1217&#x2013;26. doi:&#xa0;10.4049/jimmunol.1202388</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1202388</ArticleId><ArticleId IdType="pmc">PMC3552129</ArticleId><ArticleId IdType="pubmed">23267025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlenberg JM, Yalavarthi S, Zhao W, Hodgin JB, Reed TJ, Tsuji NM, et al. . An essential role of caspase 1 in the induction of murine lupus and its associated vascular damage. Arthritis Rheumatol (Hoboken NJ) (2014) 66(1):152&#x2013;62. doi:&#xa0;10.1002/art.38225</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38225</ArticleId><ArticleId IdType="pmc">PMC4135431</ArticleId><ArticleId IdType="pubmed">24449582</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Berthier CC, Kahlenberg JM. Enhanced inflammasome activity in systemic lupus erythematosus is mediated Via type I interferon-induced up-regulation of interferon regulatory factor 1. Arthritis Rheumatol (Hoboken NJ) (2017) 69(9):1840&#x2013;9. doi:&#xa0;10.1002/art.40166</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40166</ArticleId><ArticleId IdType="pmc">PMC5575977</ArticleId><ArticleId IdType="pubmed">28564495</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Wang H, Dai C, Wang H, Zhang H, Huang Y, et al. . P2x7 blockade attenuates murine lupus nephritis by inhibiting activation of the Nlrp3/Asc/Caspase 1 pathway. Arthritis rheumatism (2013) 65(12):3176&#x2013;85. doi:&#xa0;10.1002/art.38174</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38174</ArticleId><ArticleId IdType="pmc">PMC4038356</ArticleId><ArticleId IdType="pubmed">24022661</ArticleId></ArticleIdList></Reference><Reference><Citation>Mende R, Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Lin E, Chang J, et al. . Analysis of serum interleukin (Il)-1&#x3b2; and il-18 in systemic lupus erythematosus. Front Immunol (2018) 9:1250. doi:&#xa0;10.3389/fimmu.2018.01250</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01250</ArticleId><ArticleId IdType="pmc">PMC5999794</ArticleId><ArticleId IdType="pubmed">29930551</ArticleId></ArticleIdList></Reference><Reference><Citation>Waters ST, Fu SM, Gaskin F, Deshmukh US, Sung SS, Kannapell CC, et al. . Nzm2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci. Clin Immunol (Orlando Fla) (2001) 100(3):372&#x2013;83. doi:&#xa0;10.1006/clim.2001.5079</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/clim.2001.5079</ArticleId><ArticleId IdType="pubmed">11513551</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf SJ, Theros J, Reed TJ, Liu J, Grigorova IL, Mart&#xed;nez-Col&#xf3;n G, et al. . Tlr7-mediated lupus nephritis is independent of type I ifn signaling. J Immunol (Baltimore Md 1950) (2018) 201(2):393&#x2013;405. doi:&#xa0;10.4049/jimmunol.1701588</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1701588</ArticleId><ArticleId IdType="pmc">PMC6039244</ArticleId><ArticleId IdType="pubmed">29884703</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowling TK, Gilkeson GS. Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther (2011) 13(6):250. doi:&#xa0;10.1186/ar3528</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3528</ArticleId><ArticleId IdType="pmc">PMC3334648</ArticleId><ArticleId IdType="pubmed">22192660</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu D, Liu X, Chen S, Bao C. Expressions of il-18 and its binding protein in peripheral blood leukocytes and kidney tissues of lupus nephritis patients. Clin Rheumatol (2010) 29(7):717&#x2013;21. doi:&#xa0;10.1007/s10067-010-1386-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-010-1386-6</ArticleId><ArticleId IdType="pubmed">20140691</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis rheumatism (2008) 58(1):251&#x2013;62. doi:&#xa0;10.1002/art.23186</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23186</ArticleId><ArticleId IdType="pubmed">18163476</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita K, Yamagata T, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M, et al. . Blockade of il-18 receptor signaling delays the onset of autoimmune disease in mrl-faslpr mice. J Immunol (Baltimore Md 1950) (2004) 173(8):5312&#x2013;8. doi:&#xa0;10.4049/jimmunol.173.8.5312</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.173.8.5312</ArticleId><ArticleId IdType="pubmed">15470078</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamud MM, Ermakov EA, Boiko AS, Kamaeva DA, Sizikov AE, Ivanova SA, et al. . Multiplex analysis of serum cytokine profiles in systemic lupus erythematosus and multiple sclerosis. Int J Mol Sci (2022) 23(22). doi:&#xa0;10.3390/ijms232213829</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232213829</ArticleId><ArticleId IdType="pmc">PMC9695219</ArticleId><ArticleId IdType="pubmed">36430309</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Cai B, Zhang J, Shen B, Huang Z, Tan C, et al. . Il-1&#x3b2; and il-6 are highly expressed in Rf+Ige+ systemic lupus erythematous subtype. J Immunol Res (2017) 2017:5096741. doi:&#xa0;10.1155/2017/5096741</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/5096741</ArticleId><ArticleId IdType="pmc">PMC5329689</ArticleId><ArticleId IdType="pubmed">28286780</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal R, Bermas BL, Dayan M, Kalush F, Shearer GM, Mozes E. Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease. J Immunol (1997) 158(6):3009&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">9058840</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemir ZI, Stein H, Dworacki G, Mundel P, Koehl N, Koch B, et al. . Podocytes are the major source of il-1 alpha and il-1 beta in human glomerulonephritides. Kidney Int (1997) 52(2):393&#x2013;403. doi:&#xa0;10.1038/ki.1997.346</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1997.346</ArticleId><ArticleId IdType="pubmed">9263995</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J, Lu X, Hall G, Privratsky JR, Robson MJ, Blakely RD, et al. . Receptor signaling in podocytes limits susceptibility to glomerular damage. Am J Physiol Renal Physiol (2022) 322(2):F164&#x2013;f74. doi:&#xa0;10.1152/ajprenal.00353.2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00353.2021</ArticleId><ArticleId IdType="pmc">PMC8782651</ArticleId><ArticleId IdType="pubmed">34894725</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepburn AL, Mason JC, Wang S, Shepherd CJ, Florey O, Haskard DO, et al. . Both fcgamma and complement receptors mediate transfer of immune complexes from erythrocytes to human macrophages under physiological flow conditions in vitro. Clin Exp Immunol (2006) 146(1):133&#x2013;45. doi:&#xa0;10.1111/j.1365-2249.2006.03174.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2006.03174.x</ArticleId><ArticleId IdType="pmc">PMC1809732</ArticleId><ArticleId IdType="pubmed">16968408</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk M, Fabri M, Krutzik SR, Lee DJ, Vu DM, Sieling PA, et al. . Interleukin-1&#x3b2; triggers the differentiation of macrophages with enhanced capacity to present mycobacterial antigen to T cells. Immunology (2014) 141(2):174&#x2013;80. doi:&#xa0;10.1111/imm.12167</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12167</ArticleId><ArticleId IdType="pmc">PMC3904238</ArticleId><ArticleId IdType="pubmed">24032597</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasigli&#xe8; D, Traggiai E, Federici S, Alessio M, Buoncompagni A, Accogli A, et al. . Role of il-1 beta in the development of human T(H)17 cells: lesson from Nlpr3 mutated patients. PloS One (2011) 6(5):e20014. doi:&#xa0;10.1371/journal.pone.0020014</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020014</ArticleId><ArticleId IdType="pmc">PMC3102666</ArticleId><ArticleId IdType="pubmed">21637346</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, et al. . Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity (2009) 30(4):576&#x2013;87. doi:&#xa0;10.1016/j.immuni.2009.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.02.007</ArticleId><ArticleId IdType="pmc">PMC2705871</ArticleId><ArticleId IdType="pubmed">19362022</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivakumar S, Tsokos GC, Datta SK. T Cell receptor Alpha/Beta expressing double-negative (Cd4-/Cd8-) and Cd4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol (1989) 143(1):103&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">2525144</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A, Dean GS, Quereshi K, Isenberg DA, Lydyard PM. Characterization of Cd3+ Cd4- Cd8- (Double negative) T cells in patients with systemic lupus erythematosus: activation markers. Lupus (2002) 11(8):493&#x2013;500. doi:&#xa0;10.1191/0961203302lu235oa</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203302lu235oa</ArticleId><ArticleId IdType="pubmed">12220103</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisp&#xed;n JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, et al. . Expanded double negative T cells in patients with systemic lupus erythematosus produce il-17 and infiltrate the kidneys. J Immunol (2008) 181(12):8761&#x2013;6. doi:&#xa0;10.4049/jimmunol.181.12.8761</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.12.8761</ArticleId><ArticleId IdType="pmc">PMC2596652</ArticleId><ArticleId IdType="pubmed">19050297</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner JE, Krebs C, Tittel AP, Paust HJ, Meyer-Schwesinger C, Bennstein SB, et al. . Il-17a production by renal &#x393;&#x3b4; T cells promotes kidney injury in crescentic gn. J Am Soc Nephrol (2012) 23(9):1486&#x2013;95. doi:&#xa0;10.1681/asn.2012010040</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/asn.2012010040</ArticleId><ArticleId IdType="pmc">PMC3431412</ArticleId><ArticleId IdType="pubmed">22797181</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of il-23 and il-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol (2008) 127(3):385&#x2013;93. doi:&#xa0;10.1016/j.clim.2008.01.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2008.01.019</ArticleId><ArticleId IdType="pubmed">18373953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann rheumatic Dis (2005) 64(4):630&#x2013;3. doi:&#xa0;10.1136/ard.2004.025858</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2004.025858</ArticleId><ArticleId IdType="pmc">PMC1755442</ArticleId><ArticleId IdType="pubmed">15345502</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett TD, Fluchel M, Hersh AO, Hayward KN, Hersh AL, Brogan TV, et al. . Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis. Arthritis rheumatism (2012) 64(12):4135&#x2013;42. doi:&#xa0;10.1002/art.34661</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34661</ArticleId><ArticleId IdType="pmc">PMC3505557</ArticleId><ArticleId IdType="pubmed">22886474</ArticleId></ArticleIdList></Reference><Reference><Citation>Dein E, Ingolia A, Connolly C, Manno R, Timlin H. Anakinra for recurrent fevers in systemic lupus erythematosus. Cureus (2018) 10(12):e3782. doi:&#xa0;10.7759/cureus.3782</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.3782</ArticleId><ArticleId IdType="pmc">PMC6395019</ArticleId><ArticleId IdType="pubmed">30854270</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;bler L, Bittmann I, Kuipers JG. Macrophage activation syndrome triggered by active systemic lupus erythematosus : successful treatment by interleukin-1 inhibition (Anakinra). Z fur Rheumatologie (2020) 79(10):1040&#x2013;5. doi:&#xa0;10.1007/s00393-020-00836-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00393-020-00836-w</ArticleId><ArticleId IdType="pubmed">32804304</ArticleId></ArticleIdList></Reference><Reference><Citation>Tayer-Shifman OE, Ben-Chetrit E. Refractory macrophage activation syndrome in a patient with sle and apla syndrome - successful use of pet- ct and anakinra in its diagnosis and treatment. Modern Rheumatol (2015) 25(6):954&#x2013;7. doi:&#xa0;10.3109/14397595.2013.844403</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/14397595.2013.844403</ArticleId><ArticleId IdType="pubmed">24252009</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X, Ren Y, He X. Ifn-I mediates lupus nephritis from the beginning to renal fibrosis. Front Immunol (2021) 12:676082. doi:&#xa0;10.3389/fimmu.2021.676082</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.676082</ArticleId><ArticleId IdType="pmc">PMC8093624</ArticleId><ArticleId IdType="pubmed">33959133</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, Du Y, Cai C, Cai B, Zhu M, Xing C, et al. . Inflammasome activation negatively regulates Myd88-Irf7 type I ifn signaling and anti-malaria immunity. Nat Commun (2018) 9(1):4964. doi:&#xa0;10.1038/s41467-018-07384-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07384-7</ArticleId><ArticleId IdType="pmc">PMC6251914</ArticleId><ArticleId IdType="pubmed">30470758</ArticleId></ArticleIdList></Reference><Reference><Citation>Pujantell M, Altfeld M. Consequences of sex differences in type I ifn responses for the regulation of antiviral immunity. Front Immunol (2022) 13:986840. doi:&#xa0;10.3389/fimmu.2022.986840</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.986840</ArticleId><ArticleId IdType="pmc">PMC9522975</ArticleId><ArticleId IdType="pubmed">36189206</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark KL, Reed TJ, Wolf SJ, Lowe L, Hodgin JB, Kahlenberg JM. Epidermal injury promotes nephritis flare in lupus-prone mice. J Autoimmun (2015) 65:38&#x2013;48. doi:&#xa0;10.1016/j.jaut.2015.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2015.08.005</ArticleId><ArticleId IdType="pmc">PMC4679658</ArticleId><ArticleId IdType="pubmed">26305061</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. . Star: ultrafast universal rna-seq aligner. Bioinformatics (2013) 29(1):15&#x2013;21. doi:&#xa0;10.1093/bioinformatics/bts635</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders S, Pyl PT, Huber W. Htseq&#x2013;a Python framework to work with high-throughput sequencing data. Bioinformatics (2015) 31(2):166&#x2013;9. doi:&#xa0;10.1093/bioinformatics/btu638</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu638</ArticleId><ArticleId IdType="pmc">PMC4287950</ArticleId><ArticleId IdType="pubmed">25260700</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for rna-seq data with Deseq2. Genome Biol (2014) 15(12):550. doi:&#xa0;10.1186/s13059-014-0550-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Berthier CC, Bethunaickan R, Gonzalez-Rivera T, Nair V, Ramanujam M, Zhang W, et al. . Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J Immunol (2012) 189(2):988&#x2013;1001. doi:&#xa0;10.4049/jimmunol.1103031</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1103031</ArticleId><ArticleId IdType="pmc">PMC3392438</ArticleId><ArticleId IdType="pubmed">22723521</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju W, Nair V, Smith S, Zhu L, Shedden K, Song PXK, et al. . Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci Transl Med (2015) 7(316):316ra193. doi:&#xa0;10.1126/scitranslmed.aac7071</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aac7071</ArticleId><ArticleId IdType="pmc">PMC4861144</ArticleId><ArticleId IdType="pubmed">26631632</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. . Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum (2006) 54(9):2951&#x2013;62. doi:&#xa0;10.1002/art.22044</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22044</ArticleId><ArticleId IdType="pubmed">16947629</ArticleId></ArticleIdList></Reference><Reference><Citation>Berthier CC, Tsoi LC, Reed TJ, Stannard JN, Myers EM, Namas R, et al. . Molecular profiling of cutaneous lupus lesions identifies subgroups distinct from clinical phenotypes. J Clin Med (2019) 8(8). doi:&#xa0;10.3390/jcm8081244</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm8081244</ArticleId><ArticleId IdType="pmc">PMC6723404</ArticleId><ArticleId IdType="pubmed">31426521</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>